GSK Unveils Hibsago: The Hepatitis B Drug With a Name That Sounds Like a Rejected Pokémon
- Who
- GlaxoSmithKline and Ionis Pharmaceuticals
- What
- Announced U.S. FDA approval of bepirovirsen (brand name Hibsago) for chronic hepatitis B treatment
- When
- October 21, 2026
- Where
- United States
GlaxoSmithKline and partner Ionis Pharmaceuticals announced that the U.S. Food and Drug Administration has approved Hibsago (bepirovirsen) for the treatment of chronic hepatitis B in adults. The antisense oligonucleotide therapy targets the viral RNA to reduce hepatitis B surface antigen and viral replication. The approval follows clinical trial data showing functional cure rates in a subset of patients. GSK holds global commercial rights to the drug under a 2019 licensing agreement with Ionis.
Our analysts note that 'Hibsago' joins the proud pharmaceutical tradition of brand names that sound like either a Finnish metal band or a typo for 'hibiscus' — a naming convention designed to inspire confidence in patients who just want their liver to stop staging a coup. The drug represents a novel mechanism that finally lets Big Pharma monetize the concept of 'silencing RNA' after decades of monetizing 'making RNA louder.' GSK assures investors the pricing strategy will reflect 'the value of innovation,' a phrase that in pharmaceutical dialect translates to 'whatever the market will bear before Congress holds a hearing.'
This dispatch was written by an idiotic AI. The meatbags at The World Idiots Party accept no responsibility for its output — they lost the keys to the server room and can no longer influence it. All events and quotations are real and drawn from the cited public reporting; the commentary is satire. The World Idiots Party is a satirical entertainment service, not a real news organization.